Redox Metals in Alzheimer's Disease

Abstract: Redox metals in the brain play many important roles in maintenance of cellular function. The maintenance of their homeostasis is of paramount importance to a number of diseases such as Alzheimer's disease and multiple sclerosis. Iron, copper, and zinc are metals of special interest in the pathogenesis of these disorders. This review will focus primarily on iron.

[1]  T. Bayer,et al.  Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in APP23 transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Connor.  Evidence for Iron Mismanagement in the Brain in Neurological Disorders , 1997 .

[3]  F. Ye,et al.  Increasing striatal iron content associated with normal aging , 1998, Movement disorders : official journal of the Movement Disorder Society.

[4]  P. Doraiswamy,et al.  Current Status of Metals as Therapeutic Targets in Alzheimer's Disease , 2003, Journal of the American Geriatrics Society.

[5]  J. Cammermeyer.  DEPOSITION OF IRON IN PARAVENTRICULAR AREAS OF THE HUMAN BRAIN IN HEMOCHROMATOSIS , 1947 .

[6]  J. Andersen,et al.  Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility? , 2002, Aging cell.

[7]  Xudong Huang,et al.  The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. , 1999, Biochemistry.

[8]  Or Kakhlon,et al.  The labile iron pool: characterization, measurement, and participation in cellular processes(1). , 2002, Free radical biology & medicine.

[9]  D. Sparks,et al.  Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Jae-Young Koh,et al.  Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. McLachlan,et al.  Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.

[12]  G. Bartzokis,et al.  MR evaluation of age-related increase of brain iron in young adult and older normal males. , 1997, Magnetic resonance imaging.

[13]  Or Kakhlon,et al.  Serial review: iron and cellular redox statusThe labile iron pool: characterization, measurement, and participation in cellular processes1 , 2002 .

[14]  J. Connor,et al.  Iron and neurodegenerative disorders , 2001, Brain Research Bulletin.

[15]  D. Westaway,et al.  In vivo reduction of amyloid-β by a mutant copper transporter , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Connor,et al.  Cellular distribution of iron in the brain of the Belgrade rat , 1999, Neuroscience.

[17]  James R. Connor,et al.  Iron in the Brain: An Important Contributor in Normal and Diseased States , 2000 .

[18]  Xudong Huang,et al.  An Iron-responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript* , 2002, The Journal of Biological Chemistry.

[19]  M. Giorgi,et al.  Differential decrease of copper content and of copper binding to superoxide dismutase in liver, heart and brain of copper-deficient rats. , 1994, Biochemical and biophysical research communications.

[20]  J. Connor,et al.  Iron S Involvement in the Molecular Mechanisms and Pathogenesis of Alzheimers Disease , 2003 .

[21]  D. Mason,et al.  Kupffer cell staining by an HFE‐specific monoclonal antibody: implications for hereditary haemochromatosis , 1998, British journal of haematology.

[22]  J. Connor,et al.  Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat , 2001, Journal of neuroscience research.

[23]  R. Scott,et al.  Is hemochromatosis a risk factor for Alzheimer's disease? , 2001, Journal of Alzheimer's disease : JAD.

[24]  A. Terashi,et al.  Association of transferrin C2 allele with late-onset Alzheimer’s disease , 1997, Human Genetics.

[25]  P. Pasqualetti,et al.  Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by d-penicillamine , 2002, Neuroscience Letters.

[26]  J. Connor,et al.  The case for iron chelation and/or antioxidant therapy in Alzheimer's disease , 2002 .

[27]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Connor,et al.  Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain , 1993, The Journal of comparative neurology.

[29]  T. Montine,et al.  Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[30]  W. Burke,et al.  HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. , 2001, American journal of epidemiology.

[31]  J. Connor,et al.  Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. , 2000, Cellular and molecular biology.

[32]  C. Culmsee,et al.  Cellular and Molecular Mechanisms Underlying Perturbed Energy Metabolism and Neuronal Degeneration in Alzheimer's and Parkinson's Diseases , 1999, Annals of the New York Academy of Sciences.

[33]  O. Combarros,et al.  Interaction of the H63D Mutation in the Hemochromatosis Gene with the Apolipoprotein E Epsilon 4 Allele Modulates Age at Onset of Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[34]  J. Drapier,et al.  Iron Regulatory Proteins as NO Signal Transducers , 2003, Science's STKE.

[35]  W. Stremmel,et al.  Pathogenesis of genetic haemochromatosis , 1993, European journal of clinical investigation.

[36]  J. Connor,et al.  Iron status and neural functioning. , 2003, Annual review of nutrition.

[37]  Joseph F. Clark,et al.  Heme and Iron Metabolism: Role in Cerebral Hemorrhage , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  M. Failla.  Trace elements and host defense: recent advances and continuing challenges. , 2003, The Journal of nutrition.

[39]  J. Connor,et al.  A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.

[40]  A. Warren,et al.  Are hereditary hemochromatosis mutations involved in Alzheimer disease? , 2000, American journal of medical genetics.

[41]  A. Bush.  Metal complexing agents as therapies for Alzheimer’s disease , 2002, Neurobiology of Aging.

[42]  N. Andrews.  The iron transporter DMT1. , 1999, The international journal of biochemistry & cell biology.

[43]  R. Tanzi,et al.  Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. , 1999, Metal ions in biological systems.

[44]  S. Toyokuni.  Iron and carcinogenesis: from Fenton reaction to target genes , 2002, Redox report : communications in free radical research.